Scientists probe link between stress hormone and 'Bliss Molecule' in rare disease

NCT ID NCT02889224

Completed Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the body's natural endocannabinoids (similar to cannabis compounds) interact with the stress hormone cortisol in people with Cushing's syndrome, a condition of high cortisol. Researchers measured blood levels of these compounds in 40 participants, including those with Cushing's, obesity, and healthy controls. The goal was to understand if cortisol drives changes in endocannabinoids, which could help explain symptoms of Cushing's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could reveal how the body's natural cannabinoid system responds to cortisol, pointing toward new ways to understand or manage Cushing's syndrome.
What could go wrong: This is a small, early-stage observational study with only 40 participants. It is designed to gather knowledge, not to test a treatment, so it may not lead directly to any therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenocortical insufficiency Cushing syndrome Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUSHING'S SYNDROME

Contacts and locations

Show contact details

Locations

Service d'Endocrinologie, Hopital Haut-Leveque

Pessac, 33600, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.